Trade HRMY stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Harmony Biosciences Holdings, Inc. (HRMY) is trading at US$40.28, up 1.72% today as of Oct 9, 16:00 EDT. The company has a market capitalisation of US$2.22B. Over the past 52 weeks, HRMY has traded between US$25.52 and US$43.49. On Syfe you can trade HRMY with $0 commission and add it to your watchlist.
| Previous close | US$39.60 |
|---|---|
| Market cap | US$2.22B |
| P/E ratio | 9.51 |
| 52-week range | US$25.52 – US$43.49 |
| Volume | 487.05K |
| Exchange | US |
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Year: 2020
Harmony Biosciences Holdings Insider Sold Shares Worth $1,453,169, According to a Recent SEC Filing
Sep 9, 9:17 PM · MT Newswires
Wolfe Initiates Harmony Biosciences at Outperform With $60 Price Target
Aug 26, 11:29 AM · MT Newswires
Harmony Biosciences Holdings, Inc. (HRMY) stock is trading at US$40.28, +1.72% from the previous close of US$39.60.
The market cap for Harmony Biosciences Holdings, Inc. (HRMY) stock is approximately US$2.22B.
The price-to-earnings ratio for Harmony Biosciences Holdings, Inc. (HRMY) is 9.51, based on the latest reported earnings.
The 52-week high for Harmony Biosciences Holdings, Inc. (HRMY) stock is US$43.49.
The 52-week low for Harmony Biosciences Holdings, Inc. (HRMY) stock is US$25.52.
Harmony Biosciences Holdings, Inc. (HRMY) does not currently pay a dividend.
Stay on top of HRMY
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
